Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
112.50    0.00 (0.00%)
Bid:
111.00
Ask:
114.00
Spread: 3.00 (2.703%)
Market Cap: £15.17m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Director/PDMR Shareholding

5 May 2015 07:01

RNS Number : 0960M
Revolymer PLC
05 May 2015
 

5 May 2015

 

Revolymer plc ("Revolymer" or "the Group")

Awards under Long Term Incentive Plan and other share awards

 

Revolymer (AIM: REVO) announces the grant of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") and other share awards to its executive directors Kevin Matthews and Robin Cridland.

 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants on 30 April 2015:

· To the CEO Kevin Matthews a nil cost option over 567,568 ordinary shares

· To the CFO Robin Cridland a nil cost option over 349,550 ordinary shares.

 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 180 day period ending on the third anniversary of grant is £0.75. Between weighted average ordinary share prices of £0.75 and £1.00, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £0.75 the grants are not exercisable and lapse in full.

 

The Board also requires the executive directors to maintain minimum interests (of at least 420,000 ordinary shares for Kevin Matthews and 388,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

 

Also on 30 April 2015, the Board authorised the issue to Robin Cridland of 36,036 fully paid up ordinary shares in Revolymer plc ("New Shares") in recognition of his fulfilment of the role of Acting CEO during 2014 before the arrival of Kevin Matthews. Following the issue of the New Shares, Mr Cridland will hold 52,836 ordinary shares representing approximately 0.1% per cent. of the Company's issued share capital.

 

Application has been made to the London Stock Exchange for the 36,036 New Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8:00 am on 8 May 2015. Following Admission, the total number of ordinary shares in the Company will be 56,597,176 with each Ordinary Share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ACR under the FSA's Disclosure and Transparency Rules.

 

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

 

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Hugh Morgan / Adam James (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

 

 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) that designs, develops and formulates novel polymers to improve the performance of its customers' and partners' products.

The vision for Revolymer is to build a high growth, high quality margin, specialty materials business based on proprietary polymer technology that provides responsive or smart multi-functional materials. The Board believes that the Company's technology has broad application. Revolymer aims to generate growing high quality revenue streams by either licensing its proprietary technologies or through the supply of proprietary products using an outsourced manufacturing model. Current target markets are Household Products, Personal Care and Nicotine Gum.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEANSFEEXSEFF
Date   Source Headline
20th May 20197:00 amRNSBoard Change
3rd May 20197:00 amRNSFirst European Order for New Detergent Polymer
2nd Apr 20194:41 pmRNSSecond Price Monitoring Extn
2nd Apr 20194:35 pmRNSPrice Monitoring Extension
28th Feb 20192:05 pmRNSSecond Price Monitoring Extn
28th Feb 20192:00 pmRNSPrice Monitoring Extension
28th Feb 20199:00 amRNSPersonal care agreement with Nouryon
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
18th Feb 20197:00 amRNSFull Year Trading Update
15th Jan 20194:40 pmRNSSecond Price Monitoring Extn
15th Jan 20194:35 pmRNSPrice Monitoring Extension
15th Jan 20199:00 amRNSDetergent polymer agreement with Nouryon
9th Jan 20192:20 pmRNSBlock listing Interim Review
5th Dec 20187:00 amRNSNew Licence Agreement with New Wave
26th Oct 20187:00 amRNSDirectorate Change
2nd Oct 20187:00 amRNSBoard Changes
27th Sep 20187:00 amRNSInterim results
9th Aug 20181:41 pmRNSResult of AGM
6th Aug 20187:00 amRNSAppointment of Interim Chief Financial Officer
3rd Aug 20188:51 amRNSDirector/PDMR Dealings
3rd Aug 20188:47 amRNSBoard Changes
2nd Aug 201812:49 pmRNSExercise of Options, Directors' Dealing & TVR
2nd Aug 201811:57 amRNSResult of General Meeting
1st Aug 201810:02 amRNSResult of Open Offer & US Additional Subscription
16th Jul 20187:30 amRNSRestoration - Itaconix plc
13th Jul 20183:58 pmRNSReplacement re Further Details on the Fundraising
13th Jul 20183:54 pmRNSBlock listing Interim Review
13th Jul 20183:26 pmRNSRestoration of Trading
13th Jul 201812:11 pmRNSPosting of Circular & Annual Report & Notice of GM
12th Jul 20184:47 pmRNSFurther Details on the Fundraising
12th Jul 20187:05 amRNSProposed Fundraising
12th Jul 20187:00 amRNSPreliminary Results
29th Jun 20187:30 amRNSSuspension - Itaconix Plc
29th Jun 20187:30 amRNSSuspension of Share Trading and Financing Update
30th May 201810:00 amRNSOperational Update
16th May 20187:00 amRNSJoint marketing effort defined with AkzoNobel
16th Apr 20187:25 amRNSQ1 2018 Trading Update
13th Feb 20187:00 amRNSTrading Update
1st Feb 20187:00 amRNSBlock listing Interim Review
25th Jan 20187:00 amRNSLicence and assignment agreement with tremco
16th Oct 20179:00 amRNSSocietà Chimica Bussi investing in capacity
18th Sep 20177:00 amRNSInterim Results
5th Sep 20179:04 amRNSBio-based chelates for the detergents industry
26th Jul 20172:00 pmRNSFirst Bio-based Polymer Application Agreement
10th Jul 20177:00 amRNSBlock listing Interim Review
1st Jun 20171:19 pmRNSGrant of options
25th May 201712:42 pmRNSResult of AGM
18th May 20177:00 amRNSOperational Update
26th Apr 201711:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.